Author: Covino, Marcello; De Matteis, Giuseppe; Della Polla, Davide; Burzo, Maria Livia; Pascale, Marco Maria; Santoro, Michele; De Cristofaro, Raimondo; Gasbarrini, Antonio; De Candia, Erica; Franceschi, Francesco
Title: Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients? Cord-id: u1o404f3 Document date: 2021_7_3
ID: u1o404f3
Snippet: BACKGROUND: Patients hospitalized with COVID-19 experienced an increased risk of venous thromboembolism. AIMS: To evaluate the effect of chronic oral anticoagulation (OAC) therapy, both with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), on prognosis of COVID-19 older patients. METHODS: Single-center prospective study conducted in the Emergency Department (ED) of a teaching hospital, referral center for COVID-19 in central Italy. We evaluated all the patients ≥ 65 years, c
Document: BACKGROUND: Patients hospitalized with COVID-19 experienced an increased risk of venous thromboembolism. AIMS: To evaluate the effect of chronic oral anticoagulation (OAC) therapy, both with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), on prognosis of COVID-19 older patients. METHODS: Single-center prospective study conducted in the Emergency Department (ED) of a teaching hospital, referral center for COVID-19 in central Italy. We evaluated all the patients ≥ 65 years, consecutively admitted to our ED for confirmed COVID-19. We compared the clinical outcome of those who were on chronic OAC at ED admission with those who did not, using a propensity score matched paired cohort of controls. The primary study endpoint was all-cause in-hospital death. Patients were matched for age, sex, clinical comorbidities, and clinical severity at presentation (based on NEWS ≥ 6). Study parameters were assessed for association to all-cause in-hospital death by a multivariate Cox regression analysis to identify independent risk factor for survival. RESULTS: Although overall mortality was slightly higher for anticoagulated patients compared to controls (63.3% vs 43.5%, p = 0.012), the multivariate adjusted hazard ratio (HR) for death was not significant (HR = 1.56 [0.78–3.12]; p = 0.208). Both DOACs (HR 1.46 [0.73–2.92]; p = 0.283) and VKAs (HR 1.14 [0.48–2.73]; p = 0.761) alone did not affect overall survival in our cohort. CONCLUSIONS: Among older patients hospitalized for COVID-19, chronic OAC therapy was not associated with a reduced risk of in-hospital death. Moreover, our data suggest similar outcome both for patients on VKAs or in patients on DOACs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40520-021-01924-w.
Search related documents:
Co phrase search for related documents- adjusted hr and lymphocyte count: 1, 2, 3, 4
- admission clinical presentation and lymphocyte count: 1, 2, 3
- admission illness severity and lymphocyte count: 1, 2
- low peripheral oxygen saturation and lymphocyte count: 1
Co phrase search for related documents, hyperlinks ordered by date